Minireviews
Copyright ©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 28, 2014; 20(8): 2042-2050
Published online Feb 28, 2014. doi: 10.3748/wjg.v20.i8.2042
Table 1 Recent phase III clinical trials investigating molecular targeting agents in gastric cancer
Clinical trialBiomarkernResultsAchievement of primary objectiveRef.
HER2 inhibitor
Capecitabine/cisplatin ± trastuzumab (ToGA)HER2584PFS 6.7 mo vs 5.5 mo, P = 0.0002Positive[8]
OS 13.8 mo vs 11.1 mo, P = 0.0046
Capecitabine/oxaliplatin ± lapatinib (LOGiC)HER3545Enrollment doneNP (NCT00680901)
Paclitaxel ± lapatinib (TYTAN)HER4261OS 11.3 mo vs 8.8 mo, P = 0.2088Negative[20]
EGFR inhibitor
Capecitabine/cisplatin ± cetuximab (EXPAND)NA904PFS 5.6 mo vs 4.4 mo, P = 0.3158Negative[21]
OS 10.7 mo vs 9.4 mo, P = 0.9547
Increased toxicity
Epirubicin/oxaliplatin/capecitabine ± panitumumab (REAL-3)NA553PFS 6.0 mo vs 7.4 mo, P = 0.068Negative[22]
OS 8.8 mo vs 11.3 mo, P = 0.013
Increased toxicity
Angiogenesis inhibitor
Capecitabine/cisplatin ± bevacizumab (AVAGAST)NA774PFS 6.7 mo vs 5.3 mo, P = 0.0037Negative[23]
OS 12.1 mo vs 10.1 mo, P = 0.1002
Ramucirumab vs placebo (REGARD)NA355PFS 2.1 mo vs 1.3 mo, P < 0.0001Positive[19]
OS 5.2 mo vs 3.8 mo, P = 0.0473
Paclitaxel ± ramucirumab (RAINBOW)NA665Enrollment doneNP (NCT01170663)
Afatinib vs placeboNA270EnrollingNP (NCT01512745)
C-MET/HGF pathway inhibitor
Epirubicin/cisplatin/capecitabine ± rilotumumab (RILOMET-1)MET450EnrollingNP (NCT01697072)
Fluorouracil/folinic acid/oxaliplatin ± onartuzumab (MetGastric)MET800EnrollingNP (NCT01662869)
HER2
PI3K/Akt/mTOR pathway inhibitor
Everolimus vs placeboNA648PFS 1.68 mo vs 1.41 mo, P < 0.00001Negative[16]
OS 5.39 mo vs 4.34 mo, P = 0.1244
Paclitaxel ± everolimus (AIO-STO-0111)NA480EnrollingNP (NCT01248403)